INT78844

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.41
First Reported 1998
Last Reported 2008
Negated 0
Speculated 2
Reported most in Abstract
Documents 6
Total Number 8
Disease Relevance 4.00
Pain Relevance 2.19

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Pparg) signal transduction (Pparg) nucleus (Pparg)
enzyme binding (Pparg) DNA binding (Pparg) cytoplasm (Pparg)
Anatomy Link Frequency
Macrophages 1
brain 1
Pparg (Rattus norvegicus)
Pain Link Frequency Relevance Heat
agonist 14 100.00 Very High Very High Very High
Inflammatory response 4 99.96 Very High Very High Very High
Inflammation 6 98.64 Very High Very High Very High
Hyperalgesia 2 97.96 Very High Very High Very High
cINOD 15 97.36 Very High Very High Very High
nMDA receptor 1 65.20 Quite High
Chronic pancreatitis 1 50.00 Quite Low
tolerance 3 19.32 Low Low
ischemia 2 5.00 Very Low Very Low Very Low
cytokine 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
INFLAMMATION 15 99.96 Very High Very High Very High
Anxiety Disorder 3 98.44 Very High Very High Very High
Death 15 98.20 Very High Very High Very High
Hyperalgesia 3 97.96 Very High Very High Very High
Disease 16 93.80 High High
Drug Induced Neurotoxicity 3 83.24 Quite High
Pressure And Volume Under Development 4 82.72 Quite High
Coronary Artery Disease 13 79.44 Quite High
Immunotherapy Of Cancer 1 72.80 Quite High
Hypersensitivity 1 68.56 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Co-injection of three structurally distinct agonists of the peroxisome proliferator-activated receptor gamma (PPARgamma), including the antidiabetic thiazolidinedione troglitazone, the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen, and the prostanoid 15-deoxy-Delta(12,14) prostaglandin J(2), reduced both iNOS expression and cell death, whereas co-injection of the selective cyclo-oxygenase inhibitor NS-398 had no effect.
Regulation (Co-injection) of PPARgamma associated with inflammation, cinod, agonist and death
1) Confidence 0.41 Published 2000 Journal J. Neurosci. Section Abstract Doc Link 10995830 Disease Relevance 0.74 Pain Relevance 0.44
These data demonstrate that PPARgamma agonists can modulate inflammatory responses in brain.
Regulation (modulate) of PPARgamma in brain associated with inflammatory response and agonist
2) Confidence 0.41 Published 2000 Journal J. Neurosci. Section Abstract Doc Link 10995830 Disease Relevance 0.73 Pain Relevance 0.51
Co-injection of three structurally distinct agonists of the peroxisome proliferator-activated receptor gamma (PPARgamma), including the antidiabetic thiazolidinedione troglitazone, the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen, and the prostanoid 15-deoxy-Delta(12,14) prostaglandin J(2), reduced both iNOS expression and cell death, whereas co-injection of the selective cyclo-oxygenase inhibitor NS-398 had no effect.
Regulation (Co-injection) of peroxisome proliferator-activated receptor gamma associated with inflammation, cinod, agonist and death
3) Confidence 0.41 Published 2000 Journal J. Neurosci. Section Abstract Doc Link 10995830 Disease Relevance 0.74 Pain Relevance 0.43
Genetic variation of PPARG 54,347 C > T (designated “PPARG 161 C > T” in the publication), PPARG Pro12Ala, and PPARG 25,506 C > T as well as the association with baseline
Regulation (designated) of PPARG
4) Confidence 0.35 Published 2008 Journal PPAR Research Section Body Doc Link PMC2288645 Disease Relevance 0.39 Pain Relevance 0
We examined the effect of a specific PPARgamma agonist, rosiglitazone, on contextual fear conditioning in aged rats.
Spec (examined) Regulation (effect) of PPARgamma associated with anxiety disorder and agonist
5) Confidence 0.32 Published 2004 Journal Neuroreport Section Abstract Doc Link 15371745 Disease Relevance 0.43 Pain Relevance 0.27
This study investigated the effects of several PPARalpha and PPARgamma subtype-specific agonists on the inflammation and hyperalgesia produced by intraplantar carrageenan injection in unanesthetized male Sprague-Dawley rats.
Spec (investigated) Regulation (effects) of PPARgamma associated with hyperalgesia, inflammation and agonist
6) Confidence 0.20 Published 2002 Journal Inflammation Section Abstract Doc Link 12083418 Disease Relevance 0.74 Pain Relevance 0.44
Modification of the A/B domain, for example by physiological phosphorylation by MAP kinase, reduces ligand-binding affinity, thus negatively regulating the transcriptional and biological functions of PPAR-gamma.
Regulation (regulating) of PPAR-gamma
7) Confidence 0.20 Published 1998 Journal Nature Section Abstract Doc Link 9845075 Disease Relevance 0.22 Pain Relevance 0.11
Macrophages may be one of the targets of the PPARgamma ligand to attenuate the severity of chronic pancreatitis, partially mediated by the inhibition of proinflammatory cytokine gene expression.


Regulation (targets) of PPARgamma in Macrophages
8) Confidence 0.08 Published 2002 Journal Pancreas Section Body Doc Link 11854624 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox